NTRA ▼ -0.2% - Natera, Inc. $NTRA - Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer Natera shares fell 0.2% today despite the company announcing that its Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, a development that expands the test's market reach in a major Asia-Pacific economy. 22-SEP-2026 08:04 AM ET